[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Trevi Therapeutics Inc (TRVI)

Trevi Therapeutics Inc (TRVI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,058,710
  • Shares Outstanding, K 141,980
  • Annual Sales, $ 0 K
  • Annual Income, $ -42,760 K
  • EBIT $ -49 M
  • EBITDA $ -49 M
  • 60-Month Beta 1.07
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.83

Options Overview Details

View History
  • Implied Volatility 60.86% (-0.29%)
  • Historical Volatility 47.95%
  • IV Percentile 8%
  • IV Rank 6.10%
  • IV High 263.53% on 02/18/26
  • IV Low 47.69% on 08/22/25
  • Expected Move (DTE 5) 0.94 (6.45%)
  • Put/Call Vol Ratio 0.55
  • Today's Volume 124
  • Volume Avg (30-Day) 902
  • Put/Call OI Ratio 0.45
  • Today's Open Interest 15,562
  • Open Int (30-Day) 15,011
  • Expected Range 13.57 to 15.44

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.10
  • Number of Estimates 7
  • High Estimate $-0.06
  • Low Estimate $-0.12
  • Prior Year $-0.09
  • Growth Rate Est. (year over year) -11.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.76 +13.65%
on 04/09/26
16.12 -10.05%
on 04/20/26
+1.43 (+10.94%)
since 04/08/26
3-Month
9.82 +47.66%
on 02/19/26
16.12 -10.05%
on 04/20/26
+3.04 (+26.53%)
since 02/06/26
52-Week
5.38 +169.51%
on 06/03/25
16.12 -10.05%
on 04/20/26
+7.90 (+119.70%)
since 05/08/25

Most Recent Stories

More News
Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030

Trevi Therapeutics (NASDAQ:TRVI) outlined plans to advance Haduvio, its extended-release formulation of nalbuphine, across multiple chronic cough indications, with management emphasizing upcoming clinical...

TRVI : 14.50 (+3.20%)
Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Completed follow-on common stock offering with net proceeds of ~$162 million, extending expected cash runway into 2030 through potential FDA approval of Haduvio in IPF-related chronic cough and continued...

TRVI : 14.50 (+3.20%)
Trevi's Phase Three Timeline and Cash Burn Rate Take Center Stage Tomorrow

Barchart Research What to Expect from TRVI Earnings TRVI Generated May 4, 2026 Current Price $14.38 EPS Estimate $$-0.07 Consensus Rating Strong Buy Average Move 3.53% Trevi's Phase Three Timeline and...

TRVI : 14.50 (+3.20%)
Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference

Primary and subgroup analysis from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough accepted for oral presentation, including key subgroup analyses...

TRVI : 14.50 (+3.20%)
Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026

NEW HAVEN, Conn., April 28, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...

TRVI : 14.50 (+3.20%)
Trevi Therapeutics to Participate in Upcoming May Events

NEW HAVEN, Conn., April 23, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc.  (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral...

TRVI : 14.50 (+3.20%)
Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

NEW HAVEN, Conn., April 20, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvioâ„¢ (oral nalbuphine...

TRVI : 14.50 (+3.20%)
Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvioâ„¢ (oral nalbuphine...

TRVI : 14.50 (+3.20%)
Trevi Therapeutics Announces Proposed Public Offering of Common Stock

NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvioâ„¢ (oral nalbuphine...

TRVI : 14.50 (+3.20%)
Trevi Therapeutics to Participate in Upcoming Events

NEW HAVEN, Conn., April 01, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvioâ„¢ (oral nalbuphine...

TRVI : 14.50 (+3.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in...

See More

Key Turning Points

3rd Resistance Point 16.06
2nd Resistance Point 15.71
1st Resistance Point 15.10
Last Price 14.50
1st Support Level 14.14
2nd Support Level 13.79
3rd Support Level 13.18

See More

52-Week High 16.12
Last Price 14.50
Fibonacci 61.8% 12.02
Fibonacci 50% 10.75
Fibonacci 38.2% 9.48
52-Week Low 5.38

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.